statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright reiterated their buy rating on shares of CG Oncology (NASDAQ:CGON - Free Report) in a report issued on Thursday, Benzinga reports. HC Wainwright currently has a $75.00 target price on...

CG Oncology (NASDAQ:CGON) Receives Buy Rating from HC Wainwright

CG Oncology (NASDAQ:CGON - Get Free Report)s stock had its "buy" rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They...

CG Oncology (NASDAQ:CGON) Stock Rating Reaffirmed by HC Wainwright

Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on CG Oncology, Inc. (CGON Research Report), retaining the price target of $86.00...

Buy Rating Justified by CG Oncology's Strong Clinical Trial Results and Promising Cretosimogene Therapy

- New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting, Practice-changing Clinical Trials in Urology plenary session -IRVINE, Calif...

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

Shares of CG Oncology, Inc. (NASDAQ:CGON  Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $39.70, but opened at $38.90. CG Oncology...

CG Oncology (NASDAQ:CGON) Shares Gap Down to $39.70

CG Oncology shares have risen on the Nasdaq...

Biotech investment boosts Malin's instrinsic value

- PIVOT-006 Phase 3 open-label trial of adjuvant cretostimogene is CG Oncology's earliest disease stage clinical trial for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) - - Primary...

CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer

CG Oncology, Inc. (NASDAQ:CGON  Free Report)  Stock analysts at Cantor Fitzgerald issued their FY2023 earnings per share estimates for CG Oncology in a research report issued to clients...

CG Oncology, Inc. (NASDAQ:CGON) to Post FY2023 Earnings of ($1.23) Per Share, Cantor Fitzgerald Forecasts

Jeffrey Hung, an analyst from Morgan Stanley, has initiated a new Buy rating on CG Oncology, Inc. (CGON). Jeffrey Hung has given his Buy rating due...

Buy Rating Affirmed for CG Oncology on Cretostimogene's Clinical Success and Market Potential

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

CG Oncology initiated with bullish view at Morgan Stanley, here's why

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.

Watchers	143
52-Wk Low	$19.00
52-Wk High	$50.23

Volume	694,145.00
52-Wk High	$50.23
52-Wk Low	$19.00

CGON Cg Oncology Inc.

About

Feed

News

Sentiment

Fundamentals